|
|
1.
|
What large-scale epidemiological or genetic studies can be conducted utilizing an extensive, distributed research network linked to bio-specimen repositories?
|
|
|
|
|
1A.
|
Would these studies be of substantial immediate or sustained clinical impact?
|
|
|
|
|
1B.
|
Would these studies address currently unanswerable but pressing health questions?
|
|
|
|
|
2.
|
What additional efforts or resources should be developed to enhance the value and utility of distributed clinical databases for use in epidemiological and genetic studies, and pragmatic trials?
|
|
|
|
|
2A.
|
Standard data elements typically collected in large clinical databases include demographic variables, health services utilization, prescription drug use, and disease diagnosis (ICD codes). Which of these elements should be harmonized across database to facilitate the development of distributed research networks?
|
|
|
|
|
2B.
|
What additional data elements or information would add significant scientific value and utility to an expanded database?
|
|
|
|
|
3.
|
What additional efforts or resources should be developed to improve the collection and use of network bio-specimen repositories?
|
|
|
|
|
3A.
|
Describe the optimal model for a distributed research network bio-specimen collection.
Can current bio-repositories be expanded or adapted for this purpose or will new primary collection sites be required?
|
|
|
|
|
3B.
|
What are the advantages or disadvantages, including cost-effectiveness, of the following:
i. A large repository for each network partner
ii. A central repository for the entire network
iii. A large repository with samples from multiple networks
|
|
|
|
|
3C.
|
What are the advantages or disadvantages of using discarded clinical bio-specimens (e.g., blood, plasma, serum, urine, placenta) versus collecting bio-specimens obtained from re-contacting and consenting subjects?
|
|
|
|
|
3D.
|
What are the expected genotypic or phenotypic information that can be expected from these different types of tissue?
|
|
|
|
|
3E.
|
Are these samples adaptable to tissue microarrays?
|
|
|
|
|
3F.
|
Under what conditions would re-contacting subjects be inappropriate, unethical or impossible?
|
|
|
|
|
3G.
|
Describe the anticipated resource needs of a large scale central bio-specimen repository.
|
|
|
|
General Information:
You may provide your name and title (optional):
|
|
|